JP2010500291A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010500291A5 JP2010500291A5 JP2009523112A JP2009523112A JP2010500291A5 JP 2010500291 A5 JP2010500291 A5 JP 2010500291A5 JP 2009523112 A JP2009523112 A JP 2009523112A JP 2009523112 A JP2009523112 A JP 2009523112A JP 2010500291 A5 JP2010500291 A5 JP 2010500291A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- csfr
- csf
- pharmaceutical composition
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2006904378 | 2006-08-11 | ||
| AU2006904378A AU2006904378A0 (en) | 2006-08-11 | Treatment and prophylaxis of pulmonary disease conditions | |
| PCT/AU2007/001127 WO2008017126A1 (en) | 2006-08-11 | 2007-08-10 | Treatment of pulmonary disease conditions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010500291A JP2010500291A (ja) | 2010-01-07 |
| JP2010500291A5 true JP2010500291A5 (enExample) | 2010-09-24 |
| JP5235881B2 JP5235881B2 (ja) | 2013-07-10 |
Family
ID=39032559
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009523112A Expired - Fee Related JP5235881B2 (ja) | 2006-08-11 | 2007-08-10 | 肺疾患病態の処理 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US8574572B2 (enExample) |
| EP (2) | EP2056858B1 (enExample) |
| JP (1) | JP5235881B2 (enExample) |
| AU (1) | AU2007283463B2 (enExample) |
| CA (1) | CA2661446C (enExample) |
| DK (1) | DK2056858T3 (enExample) |
| ES (1) | ES2506065T3 (enExample) |
| NZ (1) | NZ574285A (enExample) |
| PL (1) | PL2056858T3 (enExample) |
| WO (1) | WO2008017126A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ597531A (en) * | 2009-07-31 | 2014-05-30 | Genentech Inc | Inhibition of tumor metastasis using bv8- or g-csf-antagonists |
| WO2011032204A1 (en) * | 2009-09-15 | 2011-03-24 | Csl Limited | Treatment of neurological conditions |
| RU2612884C2 (ru) * | 2010-04-02 | 2017-03-13 | Курна, Инк. | Лечение заболеваний, связанных с колониестимулирующим фактором 3 (csf3), путем ингибирования природного антисмыслового транскрипта k csf3 |
| EP2718326B1 (en) * | 2011-06-13 | 2020-08-19 | CSL Limited | Antibodies against g-csfr and uses thereof |
| CA2986097A1 (en) * | 2015-05-18 | 2016-11-24 | The University Of British Columbia | Methods and systems of detecting plasma protein biomarkers for diagnosing acute exacerbation of copd |
| JP6944701B2 (ja) * | 2016-10-21 | 2021-10-06 | 国立大学法人山口大学 | ＣＤ１１ｂアンタゴニストを含む劇症型急性肺炎治療用組成物 |
| US20210179721A1 (en) * | 2017-11-29 | 2021-06-17 | Csl Limited | Method of treating or preventing ischemia-reperfusion injury |
| US12281160B2 (en) | 2018-03-23 | 2025-04-22 | Csl Limited | Method of treating asthma |
| BR112021010920A2 (pt) * | 2018-12-04 | 2021-08-31 | CSL Innovation Pty Ltd | Método de tratamento de condições neutrofílicas |
| US12583929B2 (en) | 2020-06-04 | 2026-03-24 | CSL Innovation Pty Ltd | Method of treating acute respiratory distress syndrome |
| IL325176A (en) | 2023-07-05 | 2026-02-01 | CSL Innovation Pty Ltd | Methods for treating or preventing a complication of sickle cell disease |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
| EP0216846B2 (en) | 1985-04-01 | 1995-04-26 | Celltech Limited | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IE66494B1 (en) | 1989-09-26 | 1996-01-10 | Immunex Corp | Granulocyte-colony stimulating factor receptors |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| ES2196002T3 (es) | 1991-07-25 | 2003-12-16 | Idec Pharma Corp | Anticuerpos recombinantes para terapia humana. |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| ES2230848T3 (es) | 1998-04-28 | 2005-05-01 | Smithkline Beecham Corporation | Anticuerpos monoclonales con inmunogenicidad reducida. |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| NZ538421A (en) | 2002-08-23 | 2008-08-29 | Inst Medical W & E Hall | A method of treatment and prophylaxis |
| DE602006004555D1 (de) | 2005-01-13 | 2009-02-12 | Glaxosmithkline Zagreb | Decladinosyl-macrolide mit entzündungshemmender wirkung |
| WO2006077504A2 (en) | 2005-01-18 | 2006-07-27 | Koninklijke Philips Electronics N.V. | An algorithm for growing 4-connected cores in image segmentation |
| WO2008051260A1 (en) * | 2006-01-13 | 2008-05-02 | Battelle Memorial Institute | Methods for assessing copd-retlated diseases |
-
2007
- 2007-08-10 PL PL07784767T patent/PL2056858T3/pl unknown
- 2007-08-10 AU AU2007283463A patent/AU2007283463B2/en not_active Ceased
- 2007-08-10 WO PCT/AU2007/001127 patent/WO2008017126A1/en not_active Ceased
- 2007-08-10 ES ES07784767.1T patent/ES2506065T3/es active Active
- 2007-08-10 DK DK07784767.1T patent/DK2056858T3/da active
- 2007-08-10 CA CA2661446A patent/CA2661446C/en active Active
- 2007-08-10 EP EP07784767.1A patent/EP2056858B1/en active Active
- 2007-08-10 NZ NZ574285A patent/NZ574285A/en not_active IP Right Cessation
- 2007-08-10 US US12/377,256 patent/US8574572B2/en not_active Expired - Fee Related
- 2007-08-10 EP EP12174059.1A patent/EP2526959B1/en not_active Not-in-force
- 2007-08-10 JP JP2009523112A patent/JP5235881B2/ja not_active Expired - Fee Related
-
2013
- 2013-10-01 US US14/042,931 patent/US9376682B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010500291A5 (enExample) | ||
| Ng et al. | Interleukin-11 signaling underlies fibrosis, parenchymal dysfunction, and chronic inflammation of the airway | |
| JP2005530490A5 (enExample) | ||
| JP2011500003A5 (enExample) | ||
| JP2015519891A5 (enExample) | ||
| JP2016116520A5 (enExample) | ||
| JP2013504603A5 (enExample) | ||
| JP2022501040A5 (enExample) | ||
| JP2018126141A5 (enExample) | ||
| JP2007505627A5 (enExample) | ||
| JP2012505660A5 (enExample) | ||
| JP2014511686A5 (enExample) | ||
| JP2008546390A5 (enExample) | ||
| JP2010528601A5 (enExample) | ||
| JP2012505657A5 (enExample) | ||
| JP2011516410A5 (enExample) | ||
| JP2018510621A5 (enExample) | ||
| JP2013537423A5 (enExample) | ||
| JP2015511625A5 (enExample) | ||
| Kay et al. | Eosinophils and interleukin-5: the debate continues | |
| KR20160119259A (ko) | 낭포성 섬유증 및 cftr 이온 채널의 기능 결함과 관련된 기타 병태의 치료제로서 알기네이트 올리고머의 용도 | |
| CN115515560B (zh) | 冠状病毒感染的治疗 | |
| JP2014504857A5 (enExample) | ||
| JP2024516096A5 (enExample) | ||
| CA2558212A1 (en) | Interferon-beta for anti-virus therapy for respiratory diseases |